Monoclonal antibodies that react with the capsule of bacillus anthracis
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsZhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to monoclonal antibodies that bind poly-γ-D-glutamic acid (γDPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.
Claims26
An implantable drug infusion device, comprising:
- a pump or metering system that infuses a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody comprises a heavy chain (H) with a H-complementarity determining region (CDR)1, H-CDR2 and H-CDR3 region and a light chain (L) with a L-CDR1, L-CDR2 and L-CDR3 region, and wherein:
- (a) the heavy chain of the monoclonal antibody or antigen binding fragment comprises the H-CDR1, H-CDR2 and H-CDR3 of SEQ ID NO:
- 3 and the light chain of the monoclonal antibody or antigen binding fragment comprises the L-CDR1, L-CDR2 and L-CDR3 of SEQ ID NO:
- 4;
- or
- (b) the heavy chain of the monoclonal antibody or antigen binding fragment comprises the H-CDR1, H-CDR2 and H-CDR3 of SEQ ID NO:
- 5 and the light chain of the monoclonal antibody or antigen binding fragment comprises the L-CDR1, L-CDR2 and L-CDR3 of SEQ ID NO:
- 6,
- wherein the antibody or antigen binding fragment specifically binds poly-γ-D-glutamic acid (γDPGA), and wherein said implantable drug infusion device is implantable within a subject for infusion of the monoclonal antibody to the subject.
A pressurized drug reservoir comprising a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody comprises a heavy chain (H) with a H-complementarity determining region (CDR)1, H-CDR2 and H-CDR3 region and a light chain (L) with a L-CDR1, L-CDR2 and L-CDR3 region, wherein either:
- (a) the heavy chain of the monoclonal antibody or antigen binding fragment comprises the H-CDR1, H-CDR2 and H-CDR3 of SEQ ID NO:
- 3 and the light chain of the monoclonal antibody or antigen binding fragment comprises the L-CDR1, L-CDR2 and L-CDR3 of SEQ ID NO:
- 4;
- or
- (b) the heavy chain of the monoclonal antibody or antigen binding fragment comprises the H-CDR1, H-CDR2 and H-CDR3 of SEQ ID NO:
- 5 and the light chain of the monoclonal antibody or antigen binding fragment comprises the L-CDR1, L-CDR2 and L-CDR3 of SEQ ID NO:
- 6,
- wherein the antibody or antigen binding fragment specifically binds poly-γ-D-glutamic acid (γDPGA), wherein the pressurized drug reservoir infuses the monoclonal antibody or antigen binding fragment into a subject.
Dependencies are inferred from the claim text.